Protective Efficacy of VP1-Specific Neutralizing Antibody Associated with a Reduction of Viral Load and Pro-Inflammatory Cytokines in Human SCARB2-Transgenic Mice

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Chang, Hsuen Wen ^a   Lin, Yi Wen ^a,b   Ho, Hui Min ^a   Lin, Min Han ^a   Liu, Chia Chyi ^a   Shao, Hsiao Yun ^a   Chong, Pele ^a,c   Sia, Charles ^a,c   Chow, Yen Hung ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; EPITOPE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY N3; PROTEIN VP1; SCAVENGER RECEPTOR B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; COXSACKIEVIRUS 16 INFECTION; CYTOKINE RELEASE; DANDRUFF; DEATH; DISEASE MODEL; DRUG EFFICACY; ENTEROVIRUS 71; HAND FOOT AND MOUTH DISEASE; INJECTION; INOCULATION; LEG MUSCLE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARALYSIS; SKIN DISEASE; SPINAL CORD; TRANSGENIC MOUSE; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CAPSID PROTEINS; COXSACKIEVIRUS INFECTIONS; CROSS REACTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; GENE EXPRESSION; GENOTYPE; HAND, FOOT AND MOUTH DISEASE; HUMANS; INFLAMMATION MEDIATORS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; RECEPTORS, SCAVENGER; VIRAL LOAD;

EID: 84880802401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069858     Document Type: Article

References (43)

1. Pulli T, Koskimies P, Hyypia T, (1995) Molecular comparison of coxsackie A virus serotypes. Virology 212: 30-38.
2. Foo DG, Alonso S, Chow VT, Poh CL, (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299-1306.
3. Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 47: 3653-3662.
4. Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY, (2003) Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9: 291-293.
5. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
6. Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, et al. (2012) A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol.
7. Hashimoto I, Hagiwara A, Kodama H, (1978) Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Arch Virol 56: 257-261.
8. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, et al. (2004) A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78: 7916-7924.
9. Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA, (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73: 9969-9975.
10. Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, et al. (2005) Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 86: 3263-3269.
11. Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, et al. (2013) Human SCARB2 Transgenic Mice as an Infectious Animal Model for Enterovirus 71. PLoS One 8: e57591.
12. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15: 798-801.
13. Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, et al. (2003) Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 188: 564-570.
14. Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, et al. (2002) Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr 91: 632-635.
15. Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY, (2003) Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 36: 269-274.
16. Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, et al. (1999) Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 29: 184-190.
17. Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, et al. (2011) Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods 173: 189-195.
18. Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, et al. (2012) Human SCARB2-mediated entry and endocytosis of EV71. PLoS One 7: e30507.
19. Wang SM, Lei HY, Yu CK, Wang JR, Su IJ, et al. (2008) Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 198: 1002-1006.
20. Wang SM, Lei HY, Huang MC, Su LY, Lin HC, et al. (2006) Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol 37: 47-52.
21. Liu Q, Huang X, Ku Z, Wang T, Liu F, et al. (2012) Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J Virol Methods 187: 127-131.
22. Liu Q, Ku Z, Cai Y, Sun B, Leng Q, et al. (2011) Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 173: 115-120.
23. Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, et al. (2004) A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol 85: 69-77.
24. Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, et al. (2004) Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 85: 2981-2989.
25. Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ, et al. (2008) Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol 67: 532-542.
26. Kimura-Kuroda J, Yasui K, (1988) Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 141: 3606-3610.
27. Huang YC, Lin TY, Lin YJ, Lien RI, Chou YH, (2001) Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur J Pediatr 160: 91-94.
28. Geller TJ, Condie D, (1995) A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci 129: 131-133.
29. Komatsu H, Shimizu Y, Takeuchi Y, Ishiko H, Takada H, (1999) Outbreak of severe neurologic involvement associated with Enterovirus 71 infection. Pediatr Neurol 20: 17-23.
30. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929-935.
31. Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, et al. (1998) Fatal enterovirus 71 encephalomyelitis. J Pediatr 133: 795-798.
32. Khong WX, Foo DG, Trasti SL, Tan EL, Alonso S, (2011) Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol 85: 3067-3076.
33. McMinn P, Stratov I, Nagarajan L, Davis S, (2001) Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32: 236-242.
34. Yuan J, Liu Z, Lim T, Zhang H, He J, et al. (2009) CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 104: 628-638.
35. Yajima T, (2011) Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection. Future Microbiol 6: 551-566.
36. Bergmann CC, Lane TE, Stohlman SA, (2006) Coronavirus infection of the central nervous system: host-virus stand-off. Nat Rev Microbiol 4: 121-132.
37. Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, et al. (2012) Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol 2012: 831282.
38. Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, et al. (2010) The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 7: 47.
39. Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT, (2006) A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol 87: 2467-2476.
40. Fuller H, Del Mar C (2006) Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev: CD004883.
41. Wu SC, Liu CC, Lian WC, (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22: 3858-3864.
42. Liu CC, Lian WC, Butler M, Wu SC, (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25: 19-24.
43. Meng J, Dubreuil P, Pillot J, (1997) A new PCR-based seroneutralization assay in cell culture for diagnosis of hepatitis E. J Clin Microbiol. 35: 1373-1377.